A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. (Q32062568)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

0 references

1 reference

H L Weiner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

Canadian Journal of Neurological Sciences

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

93-101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Antigen-driven bystander suppression after oral administration of antigens

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Islet cell antigens in insulin-dependent diabetes: Pandora's box revisited

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Seasonal variation of multiple sclerosis exacerbations in Arizona.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4,

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

A population-based study of multiple sclerosis in twins: update.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

T cells responsive to myelin basic protein in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Interferon beta augments suppressor cell function in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Immunological aspects of demyelinating diseases

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Immunologic Mechanisms and Therapy in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Indictment of the microglia as the villain in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Antigen‐driven tissue‐specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein‐induced experimental autoimmune encephalomyelitis in the SJL mouse

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Exacerbations of multiple sclerosis in patients treated with gamma interferon

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Spinal cord atrophy and disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Overview of azathioprine treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

A comparison of the pathology of primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Therapy for multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Oral tolerance: immune mechanisms and treatment of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

IL-12 unmasks latent autoimmune disease in resistant mice

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Altered Th1/Th2 balance associated with non-major histocompatibility complex genes in collagen-induced arthritis in resistant and non-resistant rat strains

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Lymphocyte responses and cytokines

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

T-cell tumor necrosis factor-alpha receptor binding in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100033680

7 January 2021

10.1017/S0317167100033680

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9604129%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference